Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Willy Schwarz

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Acta Dermato-Venereologica|March 14, 2023
Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic ReviewDiva Amiri, Christopher Willy Schwarz, Lise Gether, et al.
JAMA Dermatology|June 18, 2024
Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysisGustav Hjort, Christopher Willy Schwarz, Lone Skov, et al.
Acta Dermato-Venereologica|August 28, 2020
Effect of Anti-interleukin-17 Treatment on Haemoglobin A1c LevelsChristopher Willy Schwarz, Nikolai Dyrberg Loft, Claus Zachariae, et al.
Dermatology (Basel, Switzerland)|October 13, 2020
Are Systemic Corticosteroids Causing Psoriasis Flare-Ups? Questionnaire for Danish Dermatologists, Gastroenterologists and RheumatologistsChristopher Willy Schwarz, Nikolai Loft, Vibeke Andersen, et al.
Clinical and Experimental Medicine|June 25, 2025
Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysisDaniel Isufi, Christopher Willy Schwarz, Mikkel Bak Jensen, et al.
JAMA Dermatology|October 22, 2025
Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or UstekinumabChristopher Willy Schwarz, Mads Kirchheiner Rasmussen, Trine Bertelsen, et al.
Dermatology (Basel, Switzerland)|August 10, 2025
No Change in HbA1c Levels During Treatment with Biologics or Methotrexate in Patients with PsoriasisMaheen Fatima Bukhari, Christopher Willy Schwarz, Claus Otto Carl Zachariae, et al.
The Journal of Dermatology|August 27, 2024
HLA-C*06:02 in Danish patients with psoriasis and response to biological treatmentMie Siewertsen Bergmann, Nikolai Loft, Christopher Willy Schwarz, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 20, 2024
Characteristics of Patients With Psoriasis Treated With Various Biologics - A Danish Cohort StudyChristopher Willy Schwarz, Lone Skov, Alexander Egeberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 6, 2025
Real-world experience of multiple switches between adalimumab biosimilars in patients with psoriasisOle Krogh-Jensen, Christopher Willy Schwarz, Diljit Kaur-Knudsen, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Acta Dermato-Venereologica|March 14, 2023
Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic ReviewDiva Amiri, Christopher Willy Schwarz, Lise Gether, et al.
JAMA Dermatology|June 18, 2024
Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysisGustav Hjort, Christopher Willy Schwarz, Lone Skov, et al.
Acta Dermato-Venereologica|August 28, 2020
Effect of Anti-interleukin-17 Treatment on Haemoglobin A1c LevelsChristopher Willy Schwarz, Nikolai Dyrberg Loft, Claus Zachariae, et al.
Dermatology (Basel, Switzerland)|October 13, 2020
Are Systemic Corticosteroids Causing Psoriasis Flare-Ups? Questionnaire for Danish Dermatologists, Gastroenterologists and RheumatologistsChristopher Willy Schwarz, Nikolai Loft, Vibeke Andersen, et al.
Clinical and Experimental Medicine|June 25, 2025
Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysisDaniel Isufi, Christopher Willy Schwarz, Mikkel Bak Jensen, et al.
JAMA Dermatology|October 22, 2025
Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or UstekinumabChristopher Willy Schwarz, Mads Kirchheiner Rasmussen, Trine Bertelsen, et al.
Dermatology (Basel, Switzerland)|August 10, 2025
No Change in HbA1c Levels During Treatment with Biologics or Methotrexate in Patients with PsoriasisMaheen Fatima Bukhari, Christopher Willy Schwarz, Claus Otto Carl Zachariae, et al.
The Journal of Dermatology|August 27, 2024
HLA-C*06:02 in Danish patients with psoriasis and response to biological treatmentMie Siewertsen Bergmann, Nikolai Loft, Christopher Willy Schwarz, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 20, 2024
Characteristics of Patients With Psoriasis Treated With Various Biologics - A Danish Cohort StudyChristopher Willy Schwarz, Lone Skov, Alexander Egeberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 6, 2025
Real-world experience of multiple switches between adalimumab biosimilars in patients with psoriasisOle Krogh-Jensen, Christopher Willy Schwarz, Diljit Kaur-Knudsen, et al.
Pageof 2